前列腺癌局部治疗后生化复发患者的管理。
Management of patients with biochemical recurrence after local therapy for prostate cancer.
机构信息
Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB1-1M59, Baltimore, MD 21287, USA.
出版信息
Hematol Oncol Clin North Am. 2013 Dec;27(6):1205-19, viii. doi: 10.1016/j.hoc.2013.08.005. Epub 2013 Sep 18.
Abstract
Nearly three-quarters of a million American men who have been treated with prostatectomy and/or radiation therapy experience an increasing prostate-specific antigen level known as biochemical recurrence. Although androgen-deprivation therapy remains a reasonable option for some men with biochemical recurrence, deferring androgen ablation or offering nonhormonal therapies may be appropriate in patients in whom the risk of clinical or metastatic progression and prostate cancer-specific death is low. A risk-stratified approach informed by the patient's prostate-specific antigen kinetics, comorbidities, and personal preferences is recommended to determine the best management approach.
摘要
近 70 万接受过前列腺切除术和/或放射治疗的美国男性经历了一种称为生化复发的前列腺特异性抗原水平升高。虽然雄激素剥夺疗法仍然是一些生化复发男性的合理选择，但对于那些临床或转移进展和前列腺癌特异性死亡风险较低的患者，推迟雄激素消融或提供非激素治疗可能是合适的。建议根据患者的前列腺特异性抗原动力学、合并症和个人偏好进行风险分层，以确定最佳管理方法。
相似文献
1
Management of patients with biochemical recurrence after local therapy for prostate cancer.
Hematol Oncol Clin North Am. 2013 Dec;27(6):1205-19, viii. doi: 10.1016/j.hoc.2013.08.005. Epub 2013 Sep 18.
2
Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer.
J Urol. 2017 Jun;197(6):1448-1454. doi: 10.1016/j.juro.2016.12.086. Epub 2016 Dec 19.
3
National Comprehensive Cancer Network guidelines for the management of prostate cancer.
Urology. 2003 Feb;61(2 Suppl 1):14-24. doi: 10.1016/s0090-4295(02)02395-6.
4
Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy.
J Urol. 2018 Nov;200(5):1075-1081. doi: 10.1016/j.juro.2018.04.070. Epub 2018 Apr 27.
5
Management Options for Biochemically Recurrent Prostate Cancer.
Curr Treat Options Oncol. 2017 May;18(5):26. doi: 10.1007/s11864-017-0462-4.
6
Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA.
Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1493-9. doi: 10.1016/j.ijrobp.2011.10.047. Epub 2012 Mar 6.
7
Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy.
Strahlenther Onkol. 2018 Jul;194(7):619-626. doi: 10.1007/s00066-018-1269-3. Epub 2018 Jan 30.
8
Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
Lancet Oncol. 2016 Jun;17(6):747-756. doi: 10.1016/S1470-2045(16)00111-X. Epub 2016 May 6.
9
Prostate-specific antigen doubling time subsequent to radical prostatectomy is a predictor of outcome following salvage external beam radiation therapy: a single-centre experience.
Scand J Urol. 2015 Jun;49(3):218-23. doi: 10.3109/21681805.2014.982168. Epub 2014 Nov 27.
10
Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy.
JAMA. 2008 Jun 18;299(23):2760-9. doi: 10.1001/jama.299.23.2760.
引用本文的文献
1
Long-term outcomes of PSMA PET/CT-guided radiotherapy in biochemical failure patients post-radical prostatectomy: a 5-year follow-up analysis.
Eur J Nucl Med Mol Imaging. 2025 Apr 5. doi: 10.1007/s00259-025-07255-6.
2
Treatment response assessment in mCRPC: is PSMA-PET/CT going to take the lead?
Ther Adv Med Oncol. 2024 Oct 7;16:17588359241258367. doi: 10.1177/17588359241258367. eCollection 2024.
3
Evaluation of AR, AR-V7, and p160 family as biomarkers for prostate cancer: insights into the clinical significance and disease progression.
J Cancer Res Clin Oncol. 2024 Feb 2;150(2):70. doi: 10.1007/s00432-023-05598-x.
4
Prostate cancer patient stratification by molecular signatures in the Veterans Precision Oncology Data Commons.
Cold Spring Harb Mol Case Stud. 2024 Jan 10;9(4). doi: 10.1101/mcs.a006298. Print 2023 Dec.
5
Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Long-Term Results of a Prospective Phase II Study.
Nutrients. 2023 Aug 11;15(16):3533. doi: 10.3390/nu15163533.
6
Analytical Validation of Genotyping.
Methods Protoc. 2022 Dec 31;6(1):4. doi: 10.3390/mps6010004.
7
Contrast-Enhanced Ultrasound-Magnetic Resonance Imaging Radiomics Based Model for Predicting the Biochemical Recurrence of Prostate Cancer: A Feasibility Study.
Comput Math Methods Med. 2022 Apr 28;2022:8090529. doi: 10.1155/2022/8090529. eCollection 2022.
8
The Continuum of Metastatic Prostate Cancer: Interpreting PSMA PET Findings in Recurrent Prostate Cancer.
Cancers (Basel). 2022 Mar 8;14(6):1361. doi: 10.3390/cancers14061361.
9
Development of Prostate Cancer Organoid Culture Models in Basic Medicine and Translational Research.
Cancers (Basel). 2020 Mar 25;12(4):777. doi: 10.3390/cancers12040777.
10
Combined Modality Therapies for High-Risk Prostate Cancer: Narrative Review of Current Understanding and New Directions.
Front Oncol. 2019 Nov 29;9:1273. doi: 10.3389/fonc.2019.01273. eCollection 2019.
本文引用的文献
1
Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model.
PLoS One. 2015 Oct 13;10(10):e0139440. doi: 10.1371/journal.pone.0139440. eCollection 2015.
2
Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy.
Ann Oncol. 2013 Nov;24(11):2881-6. doi: 10.1093/annonc/mdt335. Epub 2013 Aug 14.
3
Intermittent androgen suppression for rising PSA level after radiotherapy.
N Engl J Med. 2012 Sep 6;367(10):895-903. doi: 10.1056/NEJMoa1201546.
4
Temporal trends in cause of death among Swedish and US men with prostate cancer.
J Natl Cancer Inst. 2012 Sep 5;104(17):1335-42. doi: 10.1093/jnci/djs299. Epub 2012 Jul 25.
5
A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer.
Prostate Cancer Prostatic Dis. 2013 Mar;16(1):50-5. doi: 10.1038/pcan.2012.20. Epub 2012 Jun 12.
6
Changes in PSA kinetics predict metastasis- free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trials.
Cancer. 2012 Mar 15;118(6):1533-42. doi: 10.1002/cncr.26437.
7
The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up.
BJU Int. 2012 Jan;109(1):32-9. doi: 10.1111/j.1464-410X.2011.10422.x. Epub 2011 Jul 20.
8
The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation.
Prostate. 2011 Nov;71(15):1608-15. doi: 10.1002/pros.21377. Epub 2011 Mar 22.
9
Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database.
BJU Int. 2011 Aug;108(3):378-85. doi: 10.1111/j.1464-410X.2010.09878.x. Epub 2010 Nov 23.
10
Denosumab in men receiving androgen-deprivation therapy for prostate cancer.
N Engl J Med. 2009 Aug 20;361(8):745-55. doi: 10.1056/NEJMoa0809003. Epub 2009 Aug 11.
Zotero 插件